News
April 3, 2023
EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023
Structural and functional brain MRI of patients before and after neflamapimod treatment shows increased NbM volume and increased functional dynamic connectivity between NbM and deep grey matter BOSTON, MA – April 3, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced the oral presentation by academic […]
Read MoreMarch 30, 2023
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b […]
Read MoreJanuary 18, 2023
National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma’s neflamapimod in dementia with Lewy bodies
BOSTON, MA, January 18th, 2022 /PRNewswire/ – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million to support a 160-patient phase 2b study of neflamapimod in […]
Read MoreView All News
Presentations
April 27, 2023
Presentation at AD/PD™ 2023 Conference on MRI Effects of Neflamapimod on the Basal Forebrain
Read More
February 20, 2023
EIP Pharma Founder and CEO John Alam, MD, provides corporate overview at 6th Annual Neuroscience Innovation Forum in San Francisco, January 8th, 2023
Read More
View All Presentations
Corporate Presentation
Click below to download a PDF copy of EIP Pharma’s latest corporate presentation.
Download